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Induced and constitutive murine IgG-binding factors (IgG-BFs) have been purified by affinity 
chromatography from supernatants of T-cells preincubated with or without murine monoclonal IgGl and 
IgGZb, respectively. IgG-BF M, values have been studied by SDS-polyacrylamide gel electrophoresis 
(PAGE) after treatment with SDS under conditions which do not noticeably alter their immunosuppressive 
activities on the secondary in vitro IgG antibody response. Suppression was recovered at MI values of 
80000, 40000 and 20000. When induced IgG-BF was tested, the isotype-specific suppressive activity was 
found only at 40 kDa. The 20-kDa moiety appeared to derive from the 40-kDa component and the material 
found at 80 kDa exerted non-specific immunosuppressive ffects. We conclude therefore that isotype- 
specific IgG-BF has an apparent M, of 40000. 
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1. INTRODUCTION 
The production of immunoglobulin isotypes is 
specifically regulated by T-cell factors which are 
induced by a given isotype and selectively bind to 
this isotype. These factors have been called 
immunoglobulin-binding factors (IBF) [l] and 
found for IgG (IgG-BF) [2], IgE (IgE-BF) [3] and 
IgA (IgA-BF) [4]. For instance, murine IgG- 
binding factor produced spontaneously during the 
incubation of activated T-cells and of T-cell 
hybrids in serum-free medium at 37°C binds 
specifically to the Fc portion of IgG [l] and sup- 
presses secondary in vitro antibody responses of 
IgGl, IgG2a and IgG2b subclasses [1,2]. This fac- 
tor is called constitutive IgG-BF. Selective induc- 
tion of the produ~ion of subclass isoty~-specific 
IgG-BF is obtained by treatment of T-cell hybrids 
(T2D4) with monoclonal murine IgG [2]. Incuba- 
tion of T2D4 cells with IgGl leads to the produc- 
tion of a factor binding to IgGl and suppressing 
IgGl antibody synthesis. This factor is called 
IgGl -BF. Conversely, the incubation of T2D4 with 
IgG2a and IgG2b monoclonal proteins induces the 
production of IgGZBF binding to IgG2a and 
IgG2b and suppresses both IgG2a and IgG2b anti- 
body responses. 
In previous experiments, radiolabeled con- 
stitutive IgG-BF purified by affinity chromatog- 
raphy was found, by SDS-PAGE, to be composed 
of subunits of 38-40 kDa and 18-20 kDa [5,6]. 
We present here an analysis by SDS-PAGE of the 
Mr of constitutive and induced IgG-BF produced 
by the same cells and pretreated under mild 
denaturing conditions. The data, based on the sup- 
pression of the secondary in vitro IgG anti-sheep 
red blood cell (SRBC) response, show that (i) 
isotype-specific IgG-BF appears to have an Mr of 
40000, (ii) the 20-kDa subunit, although biologi- 
cally active, corresponds to degradation products 
of the 40-kDa molecule and (iii) induced and con- 
stitutive IgG-BFs have similar apparent M, values, 
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2. MATERIALS AND METHODS 
2.1. Hybridoma cells 
T2D4 T-cell hybrids were prepared as in [7] by 
fusion of alloantigen-activated T-cells with 
BW-5147 T-lymphoma cells. 
2.2. IgG-BF preparation 
Constitutive IgG-BF was isolated from super- 
natants of T2D4 cells incubated at 2 x lo6 cells/ml 
for 2 h at 37°C in serum-free balanced salt solu- 
tion (BSS) under sterile conditions. When in- 
dicated, p-methylsulfonylfluoride (PMSF; Sigma, 
St Louis, MO) at 0.001 M final concentration and 
aprotinin (Sigma) at 0.1 units/ml were added to 
cell-free supernatants. Supernatants were 10 times 
concentrated on Amicon (YM 10) filters, and ap- 
plied to affinity chromatography columns of 
Sepharose 4B (Pharmacia, France) coupled with 
rabbit IgG as in [8]. Material eluting with 0.2 M 
glycine-HCl buffer (pH 2.8), concentrated to half 
of the volume of the 10 x supernatant was used as 
constitutive IgG-BF. 
Induced IgG-BFs were prepared from 18-h 
culture supernatants of T2D4 cells preincubated 
for 2 h at 37°C with murine monoclonal IgGl or 
IgG2b. Supernatants were applied on immunoad- 
sorbents coupled with IgGl or IgG2b monoclonal 
proteins. Immunoadsorbents were washed and 
treated at acid pH [B]. Acid eluates, concentrated 
to the starting volume, were used as induced IgG- 
BFs. 
2.3. SDS-polyacrylamide gel electrophoresis 
Ninety ~1 of 10 x concentrated constitutive IgG- 
BF or of induced IgG-BFs were incubated for 
10 min at 70°C with 10~1 of 1% SDS, 30~1 of 
glycerol were then added and the mixture was ap- 
plied and run on to polyacrylamide slab gels [9] as 
in [lo]. ‘251-labeled BSA and IgG heavy and light 
chains boiled at 100°C in sample buffer [(lOro SDS, 
250 mM ,&mercaptoethanol @ME)] were run in 
parallel and used as size markers. Gel bands cor- 
responding to IgG-BF slots were cut in 0.42-mm 
slices; slices were incubated for 16 h at 37°C in 
0.5 ml RPM1 10% FCS - eluted material was 
then tested for biological activity at l/20 final dilu- 
tion. In some experiments incubation was per- 
formed in 0.5 mM Tris-HCl buffer (pH 6.8). The 
eluate of the slice located at 40 kDa was then 
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treated with 0.1% SDS for 10 min at 70°C and ap- 
plied on a second gel. 
2.4. Biological assays 
One ml cell suspension containing 6-8 x lo6 
spleen cells from mice injected 7 days before with 
10’ SRBC were restimulated with SRBC and 
cultured in RPM1 10% FCS supplemented with 
1% horse serum. Five days later, indirect plaque- 
forming cell (PFC) numbers were evaluated [l 11. 
Total IgG plaques were developed by using a rab- 
bit anti-mouse IgG antiserum at l/20 final dilu- 
tion; IgGl and IgG2b plaques were revealed by us- 
ing rabbit anti-mouse IgGl or IgG2b antisera (Lit- 
ton Bionetics, Kensington, MD) at l/10 final dilu- 
tion. IgG-BF-containing samples were added to 
cell cultures at day 0. 
3. RESULTS 
Preliminary experiments were performed to 
determine temperatures at which IgG-BF could be 
treated with SDS without losing its biological ac- 
tivity. IgG-BF was incubated for 10 min in the 
presence of 0.1% SDS at temperatures ranging 
from 0 to lOO”C, and then added, at 1: 100 final 
dilution, to secondary in vitro cultures of spleen 
cells stimulated with SRBC. The results indicated 
that the suppressive activity of IgG-BF was not 
significantly modified when it was treated at 
temperatures up to 70°C (not shown). When in- 
cubated under these conditions, size markers such 
as albumin, ovalbumin and chymotrypsinogen 
migrated lo-20% less compared to the usual 
denaturing and reducing conditions (1% SDS, 
250 mM ,&ME) (not shown). 
In a second set of experiments, constitutive IgG- 
BF was run on 12.5% acrylamide gels. Material 
eluting from each slice was then tested for 
biological activity on secondary in vitro anti-SRBC 
responses. Results of a typical experiment are 
given in fig.1. Suppressive activity was found in 
the first slice of the gel and into slices correspon- 
ding to Mr 42000 and 20000. The suppressive 
material present at the beginning of the gel 
migrated on 10% acrylamide gels at Mr 
-75000-80000 (not shown). 
Experiments were then designed to investigate 
the relationships between these 3 different peaks. 
Pretreatment of IgG-BF by dithiothreitol 
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Fig.1. SDS-PAGE (12.5% polyacrylamide gel) of 
constitutive IgG-BF. Material eluted from slices was 
added at l/20 final dilution in a secondary in vitro anti- 
SRBC response. Values indicate the percentage of 
inhibition of the indirect IgG PFC responses of duplicate 
cultures. Control response: 3220 + 108 IgG PFC/106 
cells. Arrows indicate positions of size markers. 
(0.020 M) did not modify the suppression profile 
(not shown) suggesting that the higher-M, 
molecules were probably not multimers of the 
20-kDa chain(s). When proteolytic enzyme in- 
hibitors were added to cell supernatants before 
IgG-BF purification, biological activity was pre- 
sent in only two peaks located respectively at 80 
and 40 kDa (fig.2). No suppressive material was 
found at 20 kDa. These results indicate that the 
low-M, component might correspond to degrada- 
tion products of higher-M, molecules. 
To investigate further this possibility, sup- 
pressive factor migrating at A& 40000 was eluted, 
treated with SDS, and rerun on a second gel. Sup- 
pressive activity was then found at A& 18 000 (fig.3) 
providing evidence that the 20-kDa peak cor- 
responds to biologically active degradation pro- 
ducts of the 40-kDa molecules. The same kind of 
experiment was performed with the 80-kDa peak. 
However, no significant suppressive activity was 
recovered after migration on a second gel. 
In the last set of experiments, induced IgGl-BF 
was run on polyacrylamide gels under similar con- 
ditions. Material eluting from slices was then 
tested for suppressive activity on the indirect IgGl 
anti-SRBC response. In the absence of proteolytic 
enzyme inhibitors, a suppression profile similar to 
that of constitutive IgG-BF was found (fig.4) sug- 
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Fig.2. SDS-PAGE (12.5% acrylamide gel) of 
constitutive IgG-BF prepared in the presence of 
proteolytic enzyme inhibitors. For details see fig.1. 
Control response: 2896 f 517 IgG PFC/106 cells. 
gesting structural similarity between these factors. 
In previous experiments, induced IgG-BFs were 
found to exert, depending on their dilution of use, 
both isotype-specific and non-specific suppressive 
effects. The materials eluting from slices located at 
A 
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Fig.3. SDS-PAGE (15% polyacrylamide gel) of the 
40-kDa component from constitutive IgG-BF. Control 
response: 4377 f 417 IgG PFC/106 cells. 
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Fig.4. SDS-PAGE (15% polyacrylamide gel) of induced 
IgGl-BF. Values indicate the percentage of inhibition of 
the indirect IgGl PFC response. Control response: 
2670 f 842 IgG PFC/106 cells. 
80 and 40 kDa were thus tested for their effects on 
the IgGl and IgG2b anti-SRBC responses. While 
the 80-kDa peak from both IgGl-BF and IgG2b- 
BF was found to suppress both responses, the 
40-kDa peak of IgGl-BF inhibited only the IgGl 
response and that of IgG2b-BF only the IgG2b 
IBF 
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lgGpb BF 
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Fig.5. Isotypic specificity of the 80 and 40 kDa 
components from IgGl-BF and IgG2b-BF. Control anti- 
SRBC responses: 1253 f 109 IgGl PFC/106 cells, 523 + 
116 IgG2b PFC/106 cells. 
response. In conclusion the present data provide 
evidence that isotype-specific IgG-BF has an Mr of 
40000. 
4. DISCUSSION 
In this study, our aim was to investigate the M, 
of IgG-BFs under mild denaturing conditions. The 
suppressive activities related to constitutive and in- 
duced IgG-BFs produced by the same T-cell 
hybrids were found on polyacrylamide gels at 80, 
40 and 20 kDa. The 20-kDa peak corresponds to 
degradation products of the 40-kDa molecule(s) 
since (i) rerunning of the latter on a second gel 
gives rise to 20-kDa suppressive molecules and (ii) 
the 20-kDa peak is absent when proteolytic enzyme 
inhibitors are added to cell supernatants before 
purification. These findings, together with the fact 
that isotype-specific suppressive activity of in- 
duced IgG-BFs is present only in the 40-kDa peak, 
provide evidence that IgG-BF has an iW of 40000. 
They are compatible with our recent results show- 
ing that the M, of IgG-BF present in translation 
products of mRNA isolated from the same T-cell 
hybrids is located at 37 kDa [12]. Radiolabeled 
IgG-BF produced by T-lymphoma cells and by 
alloantigen-activated T-cells was also found to be 
composed of a major chain located at 38-40 kDa 
which associates under non-reducing conditions in- 
to 80-kDa dimers [5,6]. Here, the 80-kDa peak 
could also correspond to dimers of molecules of 
smaller M, which remain associated under our ex- 
perimental conditions. However, it cannot be ex- 
cluded that it corresponds to another immunosup- 
pressive factor binding to IgG but having no 
isotypic specificity. 
Human IgG-BF was found to be composed of a 
43-kDa and of higher-M* polymers of a 23-kDa 
subunit [ 131. Other isotype-specific immunoregu- 
latory T-cell factors, namely the IgE-BFs which 
regulate the IgE response, have an Mr around 
40000 and 15000 as estimated by Sephadex G-75 
gel filtration [ 141. 
In conclusion our data provide evidence that 
isotype-specific IgG-BF has an apparent M of 
-40000 when analysed under mild denaturing con- 
ditions. Other biochemical properties of this 
molecule are currently under investigation in our 
laboratory. 
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